beloranib beloranib beloranib is a former drug candidate for the treatment of obesity. it was discovered by ckd pharmaceuticals and its clinical development was led by zafgen. drug development was halted in 2016 after deaths during clinical trials. beloranib names preferred iupac name (3r,4s,5s,6r)-5-methoxy-4--1-oxaspirooctan-6-yl (2e)-3-prop-2-enoate other names ckd-732; zgn-433 identifiers cas number 251111-30-5 y529511-79-3 (hemioxalate) y 3d model (jsmol) interactive image chemspider 5293699 n pubchem cid 6918502 unii fi471k8bu6 y4t7b8lc5i7 (hemioxalate) y comptox dashboard (epa) dtxsid40179800 inchi inchi=1s/c29h41no6/c1-20(2)7-13-24-28(3,36-24)27-26(32-6)23(15-16-29(27)19-34-29)35-25(31)14-10-21-8-11-22(12-9-21)33-18-17-30(4)5/h7-12,14,23-24,26-27h,13,15-19h2,1-6h3/b14-10+/t23-,24-,26-,27-,28+,29+/m1/s1 nkey: zezfkubilqrzck-mjscxxsssa-n ninchi=1/c29h41no6/c1-20(2)7-13-24-28(3,36-24)27-26(32-6)23(15-16-29(27)19-34-29)35-25(31)14-10-21-8-11-22(12-9-21)33-18-17-30(4)5/h7-12,14,23-24,26-27h,13,15-19h2,1-6h3/b14-10+/t23-,24-,26-,27-,28+,29+/m1/s1key: zezfkubilqrzck-mjscxxssbu smiles o=c(o2(oc)(1(oc1)cc2)3(o3c\c=c(/c)c)c)\c=c\c4ccc(occn(c)c)cc4 properties chemical formula c29h41no6 molar mass 499.648 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). n verify (what is yn ?) infobox references mechanism of action beloranib, an analog of the natural chemical compound fumagillin, is an inhibitor of the enzyme metap2. it was originally designed as angiogenesis inhibitor for the treatment of cancer. however, once the potential anti-obesity effects of metap2 inhibition became apparent, the clinical development began to focus on these effects and beloranib has shown positive results in preliminary clinical trials for this indication. clinical trials a phase i trial was published in 2013, finding a dose that led to weight loss in obese women in comparison to placebo. results from a phase ii clinical trial for obesity were promising with clinically meaningful weight loss and improvements in cardiometabolic risk factors in the treated group. zafgen continued with a phase iii trial for prader–willi syndrome. in december 2015, zafgen halted the phase iii clinical trial of beloranib for prader–willi syndrome after a second patient death in order to determine whether the deaths were treatment-related. after discussions with the food and drug administration indicated that the obstacles to gaining approval were insurmountable, product development for beloranib was ended.